uniQure (NASDAQ:QURE) Trading Up 8.4% - What's Next?

uniQure N.V. (NASDAQ:QURE - Get Free Report)'s stock price was up 8.4% during trading on Thursday . The stock traded as high as $15.71 and last traded at $15.63. Approximately 1,019,094 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 1,438,328 shares. The stock had previously closed at $14.42.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on QURE shares. HC Wainwright reiterated a "buy" rating and issued a $70.00 price target on shares of uniQure in a research note on Thursday, May 29th. Chardan Capital reaffirmed a "buy" rating and issued a $38.00 target price on shares of uniQure in a report on Friday, May 30th. Wall Street Zen cut shares of uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. Finally, Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, uniQure has an average rating of "Moderate Buy" and a consensus target price of $37.82.

uniQure Stock Performance

The company has a current ratio of 11.99, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53. The company has a market cap of $832.66 million, a price-to-earnings ratio of -3.46 and a beta of 0.08. The stock's 50 day moving average price is $14.66 and its 200 day moving average price is $13.83.

uniQure (NASDAQ:QURE - Get Free Report) last issued its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The business had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. On average, analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Insider Transactions at uniQure

In other news, Director Rachelle Suzanne Jacques sold 2,112 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director directly owned 28,346 shares in the company, valued at approximately $409,599.70. This represents a 6.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Madhavan Balachandran sold 2,112 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director owned 37,697 shares of the company's stock, valued at approximately $544,721.65. This trade represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,144 shares of company stock worth $322,426 over the last 90 days. 4.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On uniQure

Large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. increased its position in uniQure by 453.2% in the fourth quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock worth $10,836,000 after buying an additional 502,684 shares during the period. Assenagon Asset Management S.A. increased its position in uniQure by 355.2% in the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company's stock worth $3,550,000 after buying an additional 261,323 shares during the period. Raymond James Financial Inc. acquired a new stake in uniQure in the fourth quarter worth $1,951,000. Northern Trust Corp increased its position in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock worth $1,688,000 after buying an additional 1,923 shares during the period. Finally, Geode Capital Management LLC increased its position in uniQure by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 520,553 shares of the biotechnology company's stock worth $9,198,000 after buying an additional 11,951 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.